

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

HEK293-EBNA1-6E

RRID:CVCL_HF20

Type: Cell Line

Proper Citation

RRID:CVCL_HF20

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_HF20

Proper Citation: RRID:CVCL_HF20

Description: Cell line HEK293-EBNA1-6E is a Transformed cell line with a species of origin Homo sapiens (Human)

Sex: Female

Defining Citation: [PMID:21356792](#)

Comments: Characteristics: This cell line is transfected with EBNA1t, a truncated version of EBV EBNA1 lacking the Gly-Gly-Ala repeats region. It has an enhanced ability to produce recombinant protein compared to HEK293-EBNA (Cellosaurus=CVCL_6974)., Characteristics: The use of recombinant protein expression vectors containing the EBV oriP in cell lines stably expressing EBV's EBNA1 protein significantly increases recombinant protein yield., Group: Patented cell line.

Category: Transformed cell line

Organism: Homo sapiens (Human)

Name: HEK293-EBNA1-6E

Synonyms: HEK 293EBNA1-6E, HEK 293-6E, HEK293-6E, HEK2936E, 293-6E, 293Fet-clone 6E

Cross References: Wikidata:Q54882446

ID: CVCL_HF20

Hierarchy: cvcl_6642

Record Creation Time: 20220427T220329+0000

Ratings and Alerts

No rating or validation information has been found for HEK293-EBNA1-6E.

No alerts have been found for HEK293-EBNA1-6E.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 158 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Chhan CB, et al. (2026) Transgenic mouse-derived human monoclonal antibodies targeting EBV gp350 and gp42 provide basis for therapeutic development. *Cell reports. Medicine*, 7(2), 102618.

Hurlburt NK, et al. (2026) Structural basis for antibody cross-neutralization of Dengue and Zika viruses. *Communications biology*, 9(1).

Wan YH, et al. (2026) Monoclonal neutralizing antibodies elicited by infection with Kaposi sarcoma-associated herpesvirus reveal critical sites of vulnerability on gH/gL. *PLoS pathogens*, 22(1), e1013772.

McClave MK, et al. (2026) Isolation and characterization of broadly-neutralizing anti-HCMV-gB antibodies from human donors using a prefusion-stabilized HCMV gB variant. *PLoS pathogens*, 22(2), e1013950.

Carter JJ, et al. (2025) Human monoclonal antibodies to HPV16 show evidence for common developmental pathways and public epitopes. *PLoS pathogens*, 21(10), e1013086.

Lehky M, et al. (2025) A novel method for recombinant mammalian-expressed S-HBsAg virus-like particle production for assembly status analysis and improved anti-HBs serology. *Protein science : a publication of the Protein Society*, 34(1), e5251.

Edwards KR, et al. (2024) Vaccination with nanoparticles displaying gH/gL from Epstein-Barr virus elicits limited cross-protection against rhesus lymphocryptovirus. *Cell reports. Medicine*, 5(6), 101587.

Scharffenberger SC, et al. (2024) Targeting RSV-neutralizing B cell receptors with anti-idiotypic antibodies. *Cell reports*, 43(10), 114811.

Seifert L, et al. (2023) The classical pathway triggers pathogenic complement activation in membranous nephropathy. *Nature communications*, 14(1), 473.

Hussack G, et al. (2023) Structure-guided design of a potent *Clostridioides difficile* toxin A inhibitor. *Frontiers in microbiology*, 14, 1110541.

Schaefer-Babajew D, et al. (2023) Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination. *Nature*, 613(7945), 735.

van Houtum EJH, et al. (2023) Tumor cell-intrinsic and tumor microenvironmental conditions co-determine signaling by the glycoimmune checkpoint receptor Siglec-7. *Cellular and molecular life sciences : CMLS*, 80(6), 169.

Roopnarine O, et al. (2023) Fluorescence lifetime FRET assay for live-cell high-throughput screening of the cardiac SERCA pump yields multiple classes of small-molecule allosteric modulators. *Scientific reports*, 13(1), 10673.

Oskam N, et al. (2023) Factors affecting IgG4-mediated complement activation. *Frontiers in immunology*, 14, 1087532.

Sun H, et al. (2023) Protein production from HEK293 cell line-derived stable pools with high protein quality and quantity to support discovery research. *PloS one*, 18(6), e0285971.

Verstraete MM, et al. (2023) Multivalent IgM scaffold enhances the therapeutic potential of variant-agnostic ACE2 decoys against SARS-CoV-2. *mAbs*, 15(1), 2212415.

Guay KP, et al. (2023) ER chaperones use a protein folding and quality control glyco-code. *Molecular cell*, 83(24), 4524.

Korenkov M, et al. (2023) Somatic hypermutation introduces bystander mutations that prepare SARS-CoV-2 antibodies for emerging variants. *Immunity*, 56(12), 2803.

Rodarte JV, et al. (2023) Structures of drug-specific monoclonal antibodies bound to opioids and nicotine reveal a common mode of binding. *Structure (London, England : 1993)*, 31(1), 20.

K??hl L, et al. (2022) The elg technology to generate Ig-like bispecific antibodies. *mAbs*, 14(1), 2063043.